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Abstract
Secondary hyperparathyroidism (SHPT) is associated with increased bone turnover, risk of fractures, vascular calcifications,
and cardiovascular and all-cause mortality. The classical treatment for SHPT includes active vitamin D compounds and
phosphate binders. However, achieving the optimal laboratory targets is often difficult because vitamin D sterols suppress
parathyroid hormone (PTH) secretion, while also promoting calcium and phosphate intestinal absorption. Calcimimetics
increase the sensitivity of the calcium-sensing receptor, so that even with lower levels of extracellular calcium a signal can
still exist, leading to a decrease of the set-point for systemic calcium homeostasis. This enables a decrease in plasma PTH
levels and, consequently, of calcium levels. Cinacalcet was the first calcimimetic to be approved for clinical use. More than 10
years since its approval, cinacalcet has been demonstrated to effectively reduce PTH and improve biochemical control of
mineral and bone disorders in chronic kidney patients. Three randomized controlled trials have analysed the effects of
treatment with cinacalcet on hard clinical outcomes such as vascular calcification, bone histology and cardiovascular
mortality and morbidity. However, a final conclusion on the effect of cinacalcet on hard outcomes remains elusive.
Etelcalcetide is a new second-generation calcimimetic with a pharmacokinetic profile that allows thrice-weekly dosing at the
time of haemodialysis. It was recently approved in Europe, and is regarded as a second opportunity to improve outcomes by
optimizing treatment for SHPT. In this review, we summarize the impact of cinacalcet with regard to biochemical and clinical
outcomes. We also discuss the possible implications of the new calcimimetic etelcalcetide in the quest to improve outcomes.
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Introduction
Chronic kidney disease (CKD) is rapidly becoming a public health
issue, with increasing incidence and estimated worldwide
prevalence of 8–16% [1]. During the course of CKD, the decline in
renal function is accompanied by the development of disorders
of calcium and phosphate metabolism, leading to the well-
known condition ‘Mineral Bone Disease associated with CKD’
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(CKD-MBD) [2]. This condition develops due to the inability of the
kidney to excrete phosphate properly, leading to its retention and
accumulation, which stimulates fibroblast growth factor 23 (FGF-
23) and serum parathyroid hormone (PTH) [3]. FGF-23, a peptide
hormone produced mainly in the osteocytes, is able to reduce
phosphate levels using three different pathways: increased renal
excretion, PTH stimulation and calcitriol synthesis inhibition.
The latter promotes decreased gastrointestinal absorption of
phosphate and calcium, leading to hypocalcaemia. The low calci-
triol levels and hypocalcaemia also stimulate PTH secretion in
the parathyroid glands and induce the development of parathy-
roid gland hyperplasia and secondary hyperparathyroidism
(SHPT).
SHPT is associated with increased bone turnover, risk of
fractures, vascular calcifications and, most importantly, risk of
cardiovascular and all-cause mortality [4]. Recent observational
data indicate that PTH >600 pg/mL is associated with a higher
risk of cardiovascular mortality as well as all-cause cardiovas-
cular hospitalization [5]. It is interesting to note that patients
have better outcomes the longer the time that they have PTH
within recommended levels. Indeed, consistent control of bone
metabolism parameters, including PTH, within published rec-
ommended targets is a strong predictor of survival in haemo-
dialysis patients [6].
The classical treatment for SHPT includes active vitamin D
compounds and phosphate binders (to limit its gastrointestinal
phosphate absorption) [7]. However, achievement of optimal
laboratory targets is often difficult because vitamin D sterols
suppress PTH secretion, but also promote calcium and phos-
phate intestinal absorption.
Calcium-sensing receptor (CaSR) is essential for the mainte-
nance of systemic calcium homeostasis, and has become an
excellent target for the treatment of bone and mineral disor-
ders. Its ligands are called calcimimetics and can be classified
as Type 1 (agonists), such as ionized calcium and other divalent
anions that directly stimulate CaSR, or Type 2 (positive allos-
teric modulators), which bind to a site that is distinct from the
physiological ligand and increase the sensitivity of CaSR to ion-
ized calcium, leading to the decrease of the set-point for sys-
temic calcium homeostasis (homeostasis is achieved with
lower concentrations of ionized calcium). [8]. This enables a
decrease in plasma PTH levels, and consequently of calcium
levels (Table 1). Additionally, lower levels of phosphorus and
calcium  phosphorus are also seen [9], demonstrating the
capability of calcimimetics to improve the four critical disease
biomarkers associated with SHPT (the phosphorus- and cal-
cium-lowering effect distinguishes calcimimetics from active
vitamin D) [10].
First-generation compounds include phenylalkylamines R-
567 and R-568, which were tested in haemodialysis patients, but
pharmacokinetics issues halted further clinical development
[7]. Second-generation calcimimetic drugs include cinacalcet
and others that have never achieved clinical use, such as calin-
dol and AC-265347. Cinacalcet hydrochloride was the first
Type 2 calcimimetic to be approved for clinical use [11].
Treatment with cinacalcet effectively reduces PTH, calcium
and phosphorus [12]. More than 10 years since its approval,
cinacalcet has been demonstrated to effectively reduce PTH and
improve biochemical control of CKD-MBD.
Etelcalcetide is a new second-generation calcimimetic. As a
novel intravenous formulation with a pharmacokinetic profile
that allows thrice-weekly dosing (at the time of haemodialysis),
etelcalcetide was developed to improve efficacy and adherence,
and reduce gastrointestinal adverse effects relative to cinacalcet.
It was recently approved in Europe, and is regarded as a second
opportunity to improve outcomes in CKD-MBD patients by
optimizing treatment for SHPT using this promising new
calcimimetic [13].
In this review, we summarize the impact of cinacalcet in bio-
chemical and relevant clinical outcomes such as cardiovascular
mortality, vascular calcifications and fractures. We also discuss
the possible implications of the new calcimimetic etelcalcetide
in the quest to improve outcomes for CKD patients.
Cinacalcet effectively controls SHPT
Cinacalcet’s efficacy and safety has been tested in several
randomized controlled trials (RCTs) [11, 12, 14]. Cinacalcet treat-
ment in addition to active vitamin D in patients with SHPT that
is inadequately controlled despite standard therapy effectively
decreases PTH levels, while also reducing serum calcium and
phosphorus. Post hoc analysis has demonstrated that treatment
with cinacalcet improves the achievement of biochemical tar-
gets recomended by international societies [15]. In a meta-
analysis [16] involving eight trials (1429 patients) comparing
cinacalcet treatment plus standard therapy with placebo plus
standard therapy, end-of-treatment values for PTH [290.49 pg/
mL, 95% confidence interval (CI) 359.91 to 221.07], calcium
(0.85 mg/dL, 95% CI 1.14 to 0.56), phosphorus (0.29 mg/dL,
95% CI 0.50 to 0.08) and calcium  phosphorus product
(7.90 mg2/dL2, 95% CI 10.25 to 5.54) were significantly lower
with cinacalcet compared with placebo.
To allow an objective assessment of the effect of cinacalcet
on lowering PTH, the vitamin D activator receptor agonist
(VDRag) dose was kept constant. However, subsequent clinical
studies have confirmed the PTH-lowering effect of cinacalcet
used in varying or constant doses of VDRags. This is an impor-
tant finding considering that, in clinical practice, cinacalcet is
used often with VDRags [17]. Adverse effects of cinacalcet are
described in Table 2.
Besides its suppressive effect on PTH levels, data suggest
that cinacalcet treatment can induce a volume reduction of the
enlarged parathyroid glands with nodular hyperplasia seen in
SHPT patients [18].
Cinacalcet reduces FGF-23 levels
FGF-23 levels have been associated with adverse clinical out-
comes [19–24] such as progression of CKD, arterial calcification,
left ventricle hypertrophy, cardiovascular events and increased
mortality. Pharmacologic intervention capable of reducing FGF-
23 would hold the promise of having a beneficial effect on these
important clinical outcomes.
CUPID (Cinacalcet Study for Peritoneal Dialysis Patients in
Double Arm On the Lowing Effect of iPTH level), a prospective
RCT that evaluated the effect of cinacalcet on FGF-23 levels [25],
enrolled patients that had been on peritoneal dialysis for >3
months and had PTH >300 pg/mL. Patients were randomized to
Table 1. Effect of PTH-suppressive therapies on biochemical
parameters
PTH Calcium Phosphorus FGF-23
Vitamin D analogues # " " "
Cinacalcet # # # #
Etelcalcetide ## ## # ##
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cinacalcet therapy or vitamin D. The cinacalcet group had a
reduction in FGF-23 levels (3960–2325 RU/mL), whereas the con-
trol group had an increase in FGF-23 concentration (2085–2415
RU/mL). ACHIEVE (ACHIEVE: Optimizing the Treatment of SHPT:
A Comparison of Sensipar and Low Dose Vitamin D vs
Escalating Doses of Vitamin D Alone)—a Phase 4, open-label,
placebo-controlled, multicentre, RCT—was designed to compare
treatment results with escalating doses of cinacalcet plus fixed
low-dose calcitriol (cinacalcet-D group) versus calcitriol alone
(Flex-D group) [26]. Using the data of 91 subjects from this study,
Wetmore et al. verified that the percentage change of FGF-23
between the two groups differed significantly (P ¼ 0.002) [27].
In the cinacalcet-D group, the percentage change decreased
(9.7 6 18.2; P ¼ 0.021), while an increase was found in the Flex-
D group; however, the results were not significant (4.16 16.5).
The mechanism underlying the ability of cinacalcet to
decrease FGF-23 levels remains to be clarified. The CUPID inves-
tigators concluded that cinacalcet treatment was independently
associated with FGF-23 reduction, and not related to the drug’s
effects on PTH, calcium and phosphorus serum levels. Others
have observed that the decrease of FGF-23 levels is concomitant
with the decrease in phosphorus levels (but not to PTH or cal-
cium levels) [28]. Wetmore et al. suggested that calcium and
phosphorus are responsible for cinacalcet’s effect on FGF-23 lev-
els [27]. Further investigation is needed in order to understand
exactly how cinacalcet therapy results in a greater reduction of
serum FGF-23 when compared with traditional drugs.
Recently, a post hoc evaluation of the EVOLVE (Evaluation of
Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events)
study added some more information to the FGF-23 issue [29].
When analysing the results from the cinacalcet-treated patient
group (n ¼ 1338), a decrease in FGF-23 levels was seen (5555–2255
pg/mL; P < 0.001), in contrast to the control group (n ¼ 1264), where
levels remained unchanged (5600–5580 pg/mL). Moreover, when
compared with the control group, a larger proportion of patients in
the cinacalcet group had a meaningful decline (30%) of FGF-23
(28% versus 64%; P < 0.001). This finding is relevant because the
30% reduction of FGF-23 levels was associated with a decreased
risk of cardiovascular mortality (P < 0.001), sudden death (P <
0.001) and heart failure (P¼ 0.04).
Cinacalcet and fractures
Patients with CKD have increased risk of fractures compared
with the general population [30, 31]. There is also a high rate of
death and hospitalization following bone fracture among hae-
modialysis patients [32]. Abnormalities in bone structure, which
affect bone quality, are observed in patients with CKD-MBD.
Malluche et al. demonstrated that bone with high turnover had
material and nanomechanical abnormalities such as a reduced
mineral to matrix ratio [33]. Such turnover-related alterations in
bone quality may contribute to the diminished mechanical
competence of bone in CKD.
In their single centre cohort study, Iimori et al. [34] demon-
strated a U-shaped correlation between PTH level and risk of
fracture; only decreased [PTH <150 pg/mL; hazard ratio (HR)
3.27] or increased levels were related to a superior hazard of
clinical fracture (PTH >300 pg/mL; HR 2.69).
To date, no RCT has been specifically designed to evaluate
whether any compounds used in the treatment of SHPT (phos-
phate binders, vitamin D analogues or calcimimetics) decrease
the risk of fracture in CKD patients. However, treatment with
cinacalcet has been associated with reduced risk of fractures. A
combined post hoc analysis of safety data from four Phase 3
RCTs enrolling 1184 patients with end-stage renal disease
(ESRD) and uncontrolled SHPT (defined as PTH >300 pg/mL)
showed that randomization to cinacalcet, in addition to conven-
tional treatment with active vitamin D, resulted in a significant
reduction in the risk of fracture [relative risk (RR) 0.46, 95% CI
0.22–0.95, P ¼ 0.04] compared with placebo and conventional
treatment [35].
In the EVOLVE trial, in the intention-to-treat (ITT) analysis,
cinacalcet did not significantly reduced the risk of fractures [36].
During the study, more than two-thirds of patients in both
groups discontinued the treatment, so a predetermined lag-
censoring analysis (censoring time >6 months after stopping
the study drug) was performed and a relative hazard for fracture
Table 2. Lateral effects of calcimimetic agents and suggested actions to take
Side effect Frequency Proposed action
Gastrointestinal events
Nausea Very common Give cinacalcet with main meal after dialysis/in the evening
Decrease or fractionate the dose if symptoms appear after a dose
increase
Caution is advised with anti-emetics, including metoclopramide
(QT prolongation)
Vomiting Very common
Diarrhoea and dyspepsia Uncommon
Anorexia Common
Hypocalcaemia and nervous system
disorders
Hypocalcaemia Common Withhold or reduce cinacalcet until serum calcium levels reach 8 mg/
dL or symptoms have resolved
Use of calcium-based phosphate binders, vitamin D sterols or adjust-
ments of dialysis fluid calcium have been suggested by some
authors, according to clinical judgement
Dizziness and paraesthesia Common
Seizures Uncommon
Others
Skin and cutaneous disorders, rash Common Seek other causes; consider discontinuing drug
Musculoskeletal, connective tissue
and bone disorders, myalgia
Common Seek other causes; consider discontinuing drug
Immune system disorders,
hypersensitivity reactions
Uncommon Seek other causes; consider discontinuing drug
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of 0.72 (95% CI 0.58–0.90; P ¼ 0.003) was obtained. When partici-
pants were censored at the time of co-interventions, such as
parathyroidectomy and kidney transplant, the relative hazard
was 0.71 (95% CI 0.58–0.87; P ¼ 0.001). Moreover, when consider-
ing the risk of all clinical fractures (not only the first, but also
subsequent ones) the multivariable-adjusted relative hazard
was 0.83 (95% CI 0.72–0.98; P ¼ 0.02). They concluded that, when
considering events prompting discontinuation of the study
drug, such as co-interventions and cumulative clinical frac-
tures, cinacalcet reduced the rate of clinical fracture by 17–29%
[36]. These data provide suggestive evidence that cinacalcet
reduces the risk of fracture in patients with SHPT.
This effect of cinacalcet in reducing fractures is not a sur-
prising one considering two reports that used bone histomorph-
ometry from different groups to describe improved histology in
patients treated with cinacalcet [37, 38]. In the BONAFIDE (Bone
Biopsy Study for Dialysis Patients with SHPT of End Stage Renal
Disease) study [38], dialysis patients with PTH >300 pg/mL and
biopsy-proven high-turnover bone disease were treated with
cinacalcet and a second bone biopsy was performed after 6–12
months of cinacalcet treatment. Bone formation and bone reab-
sortion indices were improved; most impressive was that the
number of patients with normal bone histology increased from
none at baseline to 20 at 12 months.
The role of bone mineral density (BMD) evaluation in chronic
kidney patients is evolving. Unlike previous versions, the cur-
rent KDIGO (Kidney Disease: Improving Global Outcomes)
guidelines suggest that BMD testing is undertaken in patients
with CKD G3a-G5D with CKD-MBD and/or risk factors for osteo-
porosis if results will impact therapeutic decisions [39].
Evidence-based information is scarce about the effect of cina-
calcet on BMD in CKD patients. Some of the available data have
shown a positive effect of cinacalcet on BMD, namely on the
femoral neck [40] and proximal femur [41]. However, others
have revealed that cinacalcet therapy shows no effect on BMD
of the lumbar spine [41] or has a detrimental effect with associ-
ated bone loss on the femoral neck and lumbar spine [42]. The
effect and significance of cinacalcet on BMD remains to be
clarified.
Cinacalcet and vascular calcification
SHPT is associated with vascular calcification. Once established
in haemodialysis patients, it generally progresses much faster
than in the general population, leading to increased risk of all-
cause and cardiovascular mortality [2].
In a single-centre prospective cohort study (n ¼ 23),
Nakayama et al. [43] evaluated the impact of cinacalcet on
abdominal aortic calcification by calculating the aortic calcifica-
tion area index (ACAI) before and after treatment (12, 0, 12, 24
and 36 months). The mean ACAI values were not decreased dur-
ing the observation period (21.4% at baseline, 23.9% at 12
months, 23.7% at 24 months and 24.3% at 36 months). In addi-
tion, Tsuruta et al. [44] compared coronary artery calcification
(CAC) in cinacalcet (n ¼ 8) and control (n ¼ 60) groups, verifying
a decrease (0.094/year) in the CAC score when cinacalcet was
used, while opposite was seen in the control group the (þ0.034/
year). However, the results were not statistically significant
(P ¼ 0.102).
The ADVANCE (A Randomized Study to Evaluate the Effects
of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification
in Subjects with CKD) study [45] compared vascular and cardiac
valve calcification progression in 360 adult haemodialysis
patients with SHPT, treated either with cinacalcet plus low-dose
vitamin D (n ¼ 180) or flexible doses of vitamin D alone
(n ¼ 180). The primary endpoint was a change in the Agatston
Total CAC score (which uses the concept of plaque density and
therefore reflects the amount of calcium deposited within a cal-
cified lesion). The median percent increase in Agatston total
CAC score was 24% for the cinacalcet plus vitamin D group and
31% for in the vitamin D group (stratified median treatment dif-
ference¼10.3%; 95% CI 22.6% to 0.8%; P ¼ 0.073). Similarly,
Agatston score changes in the thoracic aorta and mitral valve
were not statistically significant. The aortic valve, on the other
hand, had a stratified median treatment difference of 44.7%
(95% CI 85.8% to 6.1%; P ¼ 0.014).
The ADVANCE study had some limitations. A substantial
number of patients assigned to the cinacalcet group received
doses of vitamin D that were higher than specified in the proto-
col. A post hoc analysis [46] comparing CAC progression among
protocol-adherent patients treated with cinacalcet showed that
the percentage increase in CAC and aortic valve calcification
was significantly slower in the cinacalcet group. Other
limitations included the open-label design and short period of
follow-up (12 months, which is unlikely to be sufficient for the
detection of substantial changes in vascular calcification).
Finally, the reduced observed calcification progression could
not be solely attributed to cinacalcet; the lower doses from vita-
min D sterols in the cinacalcet group also have to be considered.
Cinacalcet, cardiovascular disease and
all-cause mortality
Elevated serum levels of phosphorus, calcium, PTH and FGF-23
have been linked to death and cardiovascular outcomes [47–49].
In a post hoc analysis, Cunningham et al. [35] combined data on
clinical outcomes from four Phase 3 RCTs and showed that
treatment with cinacalcet resulted in a significant reduction in
the risk of cardiovascular hospitalization (HR 0.61; 95% CI 0.43–
0.86) and a non-significant tendency to reduce all-cause mortal-
ity. Another observational study, including 19 186 haemodialy-
sis patients from a large dialysis provider [50] receiving
intravenous vitamin D analogues (as a surrogate for the diagno-
sis of SHPT), found that treatment with cinacalcet was associ-
ated with significant reductions in all-cause and cardiovascular
mortality, with more pronounced survival benefits found in
patients with SHPT of greater severity. In a prospectively obser-
vational study, Block et al. [50] described a significant survival
benefit associated with cinacalcet prescription. These observa-
tions and those of others [51, 52] led to the development of a
prospective RCT evaluating the effect of cinacalcet treatment on
cardiovascular mortality. The EVOLVE [53] study was an RCT
that enrolled 3883 haemodialysis patients with moderate to
severe SHPT (median PTH 693 pg/mL) assigned to receive cina-
calcet (n ¼ 1948) or placebo (n ¼ 1935). All patients were eligible
to receive conventional treatment including phosphate binders
and vitamin D sterols. The primary composite endpoint was
time until death, myocardial infarction, hospitalization for
unstable angina, heart failure or a peripheral vascular event. In
an unadjusted ITT analysis, the primary endpoint was reached
in 48.2% of patients in the cinacalcet group and 49.2% in the pla-
cebo group (relative HR in the cinacalcet group 0.93; 95% CI 0.85–
1.02; P ¼ 0.11). After adjusting for baseline characteristics, the
relative HR for the primary composite endpoint was 0.88 (95% CI
0.79–0.97; P ¼ 0.008). In fact, despite randomization, there was
an unexpected 1-year difference in age between groups (median
age 55 years in the cinacalcet group and 54 years in the placebo
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group). As age is one of the strongest predictions of death, this
difference may have affected the results. Also, the statistical
power of the EVOLVE study was affected by high rates of treat-
ment crossover because of discontinuation in the cinacalcet
group (dropout) and use of commercially available cinacalcet in
the placebo group (drop-in). A prespecified lag-censoring analy-
sis, in which data was censored 6 months after patients stopped
cinacalcet, was performed. This analysis found a significant
reduction in the risk of primary composite endpoint (HR 0.85;
95% CI 0.76–0.95; P ¼ 0.003) and risk of death (HR 0.83; 95% CI
0.73–0.96; P ¼ 0.009) in the cinacalcet group.
Another predetermined protocol analysis compared younger
(<65 years) and older patients (65 years) [54]. Cinacalcet
reduced the risk of death and major cardiovascular events in
older but not younger patients (HR 0.70; 95% CI 0.60–0.81 for
older subjects and HR 0.97; 95% CI 0.86–1.09 for younger
subjects).
Although the primary analysis of the EVOLVE trial was nega-
tive, prespecified additional analysis showed significant reduc-
tion of the risk of death or cardiovascular outcomes, which
suggests a potential benefit of cinacalcet.
Palmer et al. [55] have published a meta-analysis of random-
ized trials that evaluated the effects of calcimimetic therapy on
mortality and adverse events in adults with CKD. Including 18
trials and a total of 7446 patients, they found that cinacalcet
had little or no effect on all-cause mortality (RR 0.97; 95% CI
0.89–1.05) and an imprecise effect on cardiovascular mortality
(RR 0.67; 95% CI 0.16–2.87). The results of this meta-analysis
should be interpreted with caution. More than half of the
patients were derived from the EVOLVE trial and this meta-
analysis only included the results from primary analysis, with
the potential setbacks discussed above. Also, all of trials
included, except the EVOLVE trial, were small and not specifi-
cally designed to assess clinically relevant outcomes such as
mortality or cardiovascular events.
New calcimimetics: etelcalcetide, a step
forward
Etelcalcetide is a novel second-generation calcimimetic agent
that was recently approved for the treatment of SHPT [13].
Etelcalcetide is a eight amino acid peptide agonist of CaSR,
which binds to CaSR by a covalent disulphide bond that results
in the allosteric activation of CaSR and consequently reduces
the circulating levels of PTH and calcium [56]. In contrast to
cinacalcet, etelcalcetide functions as a direct agonist of CaSR,
slightly activating CaSR even under calcium-free conditions
(Table 3). However, downstream signalling is stronger in the
presence of calcium; thus, the main action of etelcalcetide is
mediated through its effects as an allosteric activator [57].
Etelcalcetide has a favourable pharmacokinetic profile, with
a longer elimination half-life than cinacalcet, and half-life elim-
ination that exceeds 7 days in ESRD patients [58]. It is adminis-
tered intravenously at the end of a haemodialysis session; the
plasma concentration of etelcalcetide decreases over time but
remains relatively constant from 24 h post-dose to the next
dialysis session [13]. It is a molecule that is dialysable during
haemodialysis and, with the doses of etelcalcetide reaching
Table 3. Comparison between cinacalcet and etelcalcetide
Cinacalcet Etelcalcetide
Class Calcimimetic Calcimimetic
Year of approval (Europe) 2004 2016
Mechanism of action Interacts with membrane-spanning segments of
CaSR and enhances signal transduction, thereby
reducing PTH secretion
Peptide agonist of the CaSR that interacts with and
activates the receptor, thereby reducing PTH
secretion
Mode of administration Daily oral IV at the end of dialysis
Half-life 30–40 h >7 days
Excretion Renal (80%), faecal (15%) Renal
Interaction with CYPs Metabolized by CYP3A4, and to a lesser extent
CYP1A2; inhibits CYP2D6 (caution is advised when
prescribing potentially interacting drugs)
No significant interactions
Daily dosing (starting; maximal) 30–180 mg 2.5–15 mg/dialysis
Efficacy endpoints
>30% reduction from baseline in
mean serum PTH level during
the EAP
63.9 77.9
>50% reduction from baseline in
mean serum PTH during the EAP
40 52 (P¼ 0.001)
Adverse effects
Nausea 22.6 18.3
Vomiting 13.8 13.3
Diarrhoea 10.3 6.2
Headache 7.0 6.5
Hypertension 6.7 6.2
Hypotension 2.9 6.8
Muscle spasms 5.9 6.5
Pain in extremity 4.1 5.0
Asymptomatic hypocalcaemia 59.8 68.9
Symptomatic hypocalcaemia 2.3 5.0
Values are expressed as percentage unless indicated otherwise. EAP, efficacy assessment phase.
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between 2.5 and 5 mg at the end of a dialysis session, plasma
concentrations of etelcalcetide reach steady-state by week 4.
Although clinical experience is of course currently limited,
in vitro data show that etelcalcetide is not an inhibitor, inducer
or substrate of hepatic cytochrome (CYP) enzymes, nor is it an
inhibitor or substrate of common efflux and uptake human
transport proteins such as P-glycoprotein [59]. Thus, etelcalce-
tide is expected to have a low risk for CYP or transporter-
mediated drug interactions.
The immunogenicity risk of etelcalcetide has been evaluated
[60]. While both preexisting anti-etelcalcetide antibodies and
those that developed after treatment were detected, no conse-
quences have been reported regarding the clinical exposure,
efficacy or safety of etelcalcetide.
Pivotal trials testing etelcalcetide in the treatment of SHPT
were recently published [61, 62]. Two parallel Phase 3 placebo-
controlled trials were conducted in 1023 haemodialysis patients
with moderate to severe hyperparathyroidism. Intravenous
administration of etelcalcetide (n¼ 503) or placebo (n¼ 513) after
each haemodialysis session for 26 weeks was performed.
Patients randomized to etelcalcetide were significantly more
likely to achieve the primary efficacy endpoint (a reduction
>30% in baseline PTH: 74.0–75.3% in the etelcalcetide group ver-
sus 8.3–9.6% in the placebo group). In addition, patients
randomized to etelcalcetide were significantly more likely to
achieve a PTH level of 300 pg/mL or lower (49.6–53.3% in the
etelcalcetide group versus 4.6–5.1% in the placebo group). The
median dose of etelcalcetide during the efficacy assessment
phase was 5.0 and 7.1 mg, respectively. Patients randomized to
etelcalcetide were more likely to experience substantial lower-
ing of FGF-23 despite more frequent provision of calcium and
vitamin D. Treatment with etelcalcetide decreased bone-
specific alkaline phosphatase and collagen Type 1 cross-linked
C-telopeptide. Patients randomized to etelcalcetide had more
muscle spasms, nausea and vomiting than the placebo group.
Hypocalcaemia occurred in 63.8% of patients, but symptomatic
hypocalcaemia was reported in only 7% of patients assigned to
etelcalcetide. Similar results were obtained in a placebo-
controlled trial from Japan, which tested the efficacy and safety
of etelcalcetide [63].
A randomized double-bind, double-dummy active clinical
trial has been conducted that compared intravenous etelcalce-
tide versus oral placebo and oral cinacalcet versus intravenous
placebo in 683 haemodialysis patients with PTH higher than 500
pg/mL [62]. The primary efficacy endpoint was non-inferiority
of etelcalcetide at achieving more than a 30% reduction from
baseline in mean predialysis PTH concentration, and secondary
endpoints included superiority in achieving biochemical
Fig. 1. Parathyroid hormone, calcium and phosphate concentrations in patients receiving cinacalcet or etelcalcetide. Reproduced with permission from Block et al. [62].
Old and new calcimimetics | 85
endpoints (>50% and >30% reduction in PTH) and self-reported
nausea or vomiting. Etelcalcetide was not inferior to cinacalcet
in reducing PTH concentration and also met superior criteria.
The proportion of patients who achieved >30% PTH reduction
was 68.2% in the etelcalcetide group and 57.7% in the cinacalcet
group (Figure 1). There was also a significant difference in the
proportion of patients who achieved >50% reduction of PTH.
Hypocalcaemia was more frequent in etelcalcetide group (68.9%
versus 59.8%) and the mean number of days of vomiting or nau-
sea were not significantly different. Overall safety and tolerabil-
ity between etelcalcetide and cinacalcet were similar. There
was a numerically higher number of heart failure episodes in
the etelcalcetide group, but overall the event rates were very
low and similar to those observed in the EVOLVE trial.
The effect of etelcalcetide on FGF-23 levels is also notewor-
thy. Etelcalcetide treatment yielded a more pronounced
reduction in FGF-23 levels than cinacalcet. As discussed above,
FGF-23 is elevated in CKD patients and has been associated
with adverse outcomes such as left ventricular hypertrophy and
cardiac failure. In the EVOLVE trial, a 30% reduction of FGF-23
levels was associated with significant reduction of the primary
composite endpoint, heart failure and death [29]. This promis-
ing finding in the etelcalcetide group raises the possibility of a
more pronounced impact on cardiovascular outcomes.
There are some important clinical aspects considering the
results of the trials mentioned above that we want to highlight.
Etelcalcetide is superior to cinacalcet in achieving a reduction of
PTH and FGF-23 concentrations in ESRD patients; however, it
also leads to more frequent episodes of hypocalcaemia. Data
suggest that this hypocalcaemic effect could be more pro-
nounced at the beginning of treatment when PTH is highest.
Indeed, in a multinational placebo-controlled trial, the calcium-
lowering effect of etelcalcetide was evident early after treat-
ment initiation and reached a nadir by weeks 10–12. This
calcium-lowering effect was observed despite increased use of
oral calcium-containing binders and active vitamin D ana-
logues, and increases in dialysate calcium concentration in an
important proportion of patients. This observation raises legiti-
mate concerns regarding the possible cumulative positive cal-
cium balance. Etelcalcetide is given at the end of haemodialysis
sessions, which improves medication adherence and reduces
pill burden. Etelcalcetide does not seem to result in fewer gas-
trointestinal symptoms related to calcimimetic treatment
despite intravenous administration, in contrast to what was
previously anticipated. The nausea and vomiting induced by
cinacalcet and etelcalcetide appears to be a systemic effect
rather than a local gastrointestinal class effect.
Finally, it is tempting to speculate that the longer elimina-
tion half-life of etelcalcetide could lead to more stable control of
biochemical parameters like PTH and calcium phosphate, and
that such a sustained suppression of PTH could translate into
improved bone turnover and metabolism, decreased vascular
calcification and, ultimately, improved cardiovascular patient
outcomes. Any impact on such important outcomes remains to
be identified.
Conclusion
In conclusion, SHPT is associated with increased bone turnover,
risk of fractures, vascular calcifications, and cardiovascular and
all-cause mortality. Cinacalcet, the first calcimimetic approved
for clinical use, effectively reduces PTH and improves biochemi-
cal control of mineral and bone disorders in CKD patients.
However, the effect of cinacalcet on hard outcomes remains to
be proved.
Etelcalcetide, a new second-generation calcimimetic, is
superior to cinacalcet in achieving the reduction of PTH and
FGF-23 concentrations in ESRD patients, but also leads to more
frequent episodes of hypocalcaemia that could be more pro-
nounced at beginning of treatment. Etelcalcetide is given at the
end of haemodialysis sessions, which improves medication
adherence and reduces pill burden. However, etelcalcetide does
not seem to cause fewer gastrointestinal symptoms despite
intravenous administration.
In our view, etelcalcetide represents a significant advance in
the treatment of SHPT, via better control of PTH and FGF-23 lev-
els and improved adherence. However, whether this improved
biochemical control translates into improved clinical outcomes
such as bone fracture rate and cardiovascular morbidity and
mortality remains to be elucidated by prospective randomized
trials.
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